DCOY Decoy Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1615219 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-231.0%
TTM EPS YoY118.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-11,102.9%
ROA-222.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets48.3%
Debt / equity0.00x
Current ratio1.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.56x
Accruals ratio-98.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | $0 | $1.84M |
| R&D expense | $368,170 | $770,027 | $7.17M | $15.84M | $8.55M |
| SG&A expense | $3.73M | $4.96M | $5.72M | $7.14M | $6.10M |
| Operating income | -$12.61M | -$5.73M | -$12.89M | -$31.84M | -$12.81M |
| Income tax | $0 | — | — | — | — |
| Net income | -$12.52M | -$5.58M | -$12.54M | -$31.61M | -$12.77M |
| EBITDA | -$12.61M | -$5.73M | -$12.88M | -$31.83M | -$12.79M |
| EPS (basic) | -129.10 | -69.54 | -30.74 | -14.88 | -7.72 |
| EPS (diluted) | -129.10 | -69.54 | -30.74 | -14.88 | -7.72 |
| Weighted avg. shares (diluted) | 96,967 | 80,184 | 408,078 | 2.12M | 1.65M |
| Balance sheet | |||||
| Cash & equivalents | $10.71M | $2.43M | $5.90M | $12.11M | $29.21M |
| Receivables | — | — | — | — | $1.60M |
| Current assets | $10.99M | $2.99M | $6.52M | $14.52M | $30.16M |
| PP&E, net | $40,559 | $0 | — | — | $7,880 |
| Goodwill | — | — | — | $0 | $8.87M |
| Total assets | $11.06M | $3.02M | $6.59M | $14.65M | $40.83M |
| Current liabilities | $5.17M | $1.51M | — | — | — |
| Total liabilities | $5.17M | $1.51M | $1.30M | $4.27M | $2.11M |
| Shareholders' equity | $5.89M | $1.51M | $5.29M | $10.38M | $38.72M |
| Shares outstanding | 531,968 | 96,077 | 492,304 | 2.26M | 1.81M |
| Cash flow statement | |||||
| Operating cash flow | -$4.83M | -$4.53M | -$12.85M | -$17.60M | -$10.20M |
| Capital expenditure | $577,000 | $0 | — | — | $0 |
| Free cash flow | -$5.40M | -$4.53M | — | — | -$10.20M |
| Investing cash flow | $764,735 | $0 | $0 | -$1.50M | $0 |
| Financing cash flow | $12.34M | $1.06M | $6.64M | $1.99M | $28.30M |
| Depreciation & amortization | $7,151 | $4,424 | $10,051 | $6,677 | $19,183 |
| Stock-based compensation | $219,058 | $273,730 | $524,838 | $796,803 | $559,044 |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.